Frontier Space Technologies

Frontier Space Technologies is a UK-based space biotechnology company that develops autonomous, modular laboratory platforms for research and biomanufacturing in microgravity. Founded as a spin-out from Cranfield University in 2021, the company's flagship product, SpaceLab, enables pharmaceutical companies to conduct complex experiments—including protein crystallization, 3D cell culture, and organ-on-a-chip studies—in low Earth orbit. By leveraging the unique environment of space, Frontier Space aims to optimize drug formulations, such as transitioning therapies from intravenous to subcutaneous administration, and accelerate disease modeling. The company successfully launched its first orbital mission, SpaceLab Mark 1, in April 2025, validating its core technology for scalable in-space science. Frontier Space maintains strategic partnerships with academic institutions like Imperial College London and commercial partners to democratize access to orbital R&D for the life sciences sector.